Menlo Therapeutics and Foamix Pharmaceuticals Complete Merger, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic IndicationsGlobeNewsWire • 03/09/20
Menlo Therapeutics shares slide 25% premarket after trial of treatment for severe itching fails to meet goalsMarket Watch • 02/26/20
Menlo Therapeutics Announces Results from Phase 2 Trial of Serlopitant in Patients with Chronic Pruritus of Unknown OriginGlobeNewsWire • 02/26/20
Menlo Therapeutics Announces Publication of Phase 2 Results for Serlopitant for the Treatment of Pruritus Associated with Psoriasis in the Journal of the American Academy of DermatologyGlobeNewsWire • 02/05/20
Foamix Pharmaceuticals Ltd. (FOMX) CEO Dave Domzalski on Q3 2019 Earnings & Merger Announcement with Menlo Therapeutics Conference (Transcript)Seeking Alpha • 11/12/19
Foamix and Menlo Therapeutics to Merge, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic IndicationsGlobeNewsWire • 11/11/19
Menlo Therapeutics And Serlopitant In Pruritogenic Prurigo Nodularis: On TrackSeeking Alpha • 11/01/19
Menlo Therapeutics Announces Completion of Enrollment in Two Phase 3 Trials of Serlopitant in Prurigo NodularisGlobeNewsWire • 10/29/19
Menlo Therapeutics Presents Successful Phase 2 Clinical Trial Results of Serlopitant in Psoriasis at the European Academy of Dermatology and Venereology MeetingGlobeNewsWire • 10/11/19
Menlo Therapeutics to Present at the 2019 Cantor Global Healthcare ConferenceGlobeNewsWire • 09/26/19
Menlo Therapeutics Announces Completion of Enrollment of 233 Patients in Phase 2 Trial of Serlopitant in Patients with Chronic Pruritus of Unknown OriginGlobeNewsWire • 09/24/19
Menlo Therapeutics to Present at the HC Wainwright 21st Annual Global Investment ConferenceGlobeNewsWire • 08/29/19